Thomas J. Schall, Ph.D.President, Chief Executive Officer and Chairman of the Board
Dr. Schall is the founder of our company and has served as our President, Chief Executive Officer and Director since we commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall’s laboratories have been responsible for the discovery or co-discovery of a large percentage of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.
Susan M. KanayaExecutive Vice President, Chief Financial and Administrative Officer and Secretary
Ms. Kanaya has served as our Executive Vice President, Chief Financial and Administrative Officer since October 2016 and as Secretary since February 2006. From January 2006 to October 2016, Ms. Kanaya served as our Senior Vice President, Finance, and Chief Financial Officer. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.
Markus J. Cappel, Ph.D.Chief Business Officer and Treasurer
Dr. Cappel has served as our Chief Business Officer since February 2007, and Treasurer since August 2004. From March 2003 to February 2007, he served as our Senior Vice President of Corporate and Business Development. From October 2001 to March 2003, Dr. Cappel served as our Vice President of Business Development. Prior to joining us, Dr. Cappel served as Vice President of Business Development at Alkermes, Inc., from 1998 to 2001. Prior to this, he served as Director of Business Development with Millennium Pharmaceuticals as well as in various business development roles at Cygnus, Inc. Dr. Cappel received his B.S. in pharmacy and his Ph.D. in pharmaceutics from J.W. Goethe University, Frankfurt, Germany, and his M.B.A. from Harvard Business School. Dr. Cappel also completed postdoctoral studies in pharmaceutics at the University of Michigan.
Catherine L. Kelleher, M.D.Senior Vice President, Clinical Development
Dr. Kelleher has served as our Senior Vice President, Clinical Development since April 2019. Since 2016, Dr. Kelleher has worked as a consultant for multiple companies in the development and growth of clinical programs in different therapeutic areas including nephrology and rare disease. Dr. Kelleher also held the position of Vice President of Clinical Development at Viking Therapeutics in 2016. From 2015 – 2016, she served as Head of Clinical Affairs at Proteus Digital Health and Vice President of Clinical Development at Coherus Biosciences, respectively. From 2008 to 2015, Dr. Kelleher worked at Amgen in different roles including Clinical Research Medical Director in Nephrology and Global Safety Officer across several therapeutic areas. Dr. Kelleher also held several academic positions from 1994 to 2008, including Associate Professor of Medicine at the University of Colorado School of Medicine, and Instructor in Medicine at Harvard Medical School. She completed clinical fellowships in nephrology and geriatrics at Beth Israel Hospital and Harvard Medical School respectively, a research fellowship in the Department of Genetics at Harvard Medical School. and an internship/residency in Internal medicine at Johns Hopkins Hospital. Dr. Kelleher received her M.D. from the University of Washington, School of Medicine; and received a B.S. from The Johns Hopkins University School of Health Services.
Dalia R. Rayes, MBASenior Vice President, Head of Commercial
Ms. Rayes has served as our Senior Vice President and Head of Commercial since January 2019, having joined ChemoCentryx as Vice President of Marketing in May 2018. Before joining ChemoCentryx, Ms. Rayes was at Actelion Pharmaceuticals US for 12 years. From 2013 to 2015 she served as Head of a Business Unit, during which she successfully launched a cutaneous lymphoma product and built the commercial infrastructure for the sales and marketing teams. From 2005 to 2013, she served as the Director of Franchise Strategy and Operations, Associate Director of Pulmonary Arterial Hypertension Marketing, and Senior Product Manager. Prior to her work at Actelion, she held various sales and marketing roles at Algorithm Pharmaceuticals, which included managing brand teams across 13 countries in the Middle East and North Africa. Ms. Rayes received her MBA from Lebanese American University in Beirut and her B.S. in Pharmacy from Beirut Arab University.
Rajinder Singh, Ph.D.Senior Vice President, Head of Pharmaceutics
Dr. Singh has served as our Senior Vice President, Head of Pharmaceutics since May 2019, having joined ChemoCentryx as Senior Vice President, Research in May 2016. Before joining us, Dr. Singh held various management positions at Rigel Pharmaceuticals, Inc. (Rigel). Most recently and for the past ten years, Dr. Singh was Vice President, Chemistry at Rigel, where he oversaw the advancement of several drug candidates from discovery to clinical development, which included the filing of numerous Investigational New Drug applications in the areas of immunology and oncology. Prior to joining Rigel, Dr. Singh was a lead chemist at Chiron Corporation from 1994 to 1998. From 1992 to 1994, Dr. Singh was a Postdoctoral Fellow at Eli Lilly & Company. Dr. Singh received his Ph.D. degree in Organic Chemistry from the University of Oxford.